<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383474</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00147</org_study_id>
    <secondary_id>NCI-2009-00147</secondary_id>
    <secondary_id>CDR0000502258</secondary_id>
    <secondary_id>MCC-14796</secondary_id>
    <secondary_id>7306</secondary_id>
    <secondary_id>N01CM62208</secondary_id>
    <secondary_id>P30CA076292</secondary_id>
    <nct_id>NCT00383474</nct_id>
  </id_info>
  <brief_title>Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase</brief_title>
  <official_title>A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in&#xD;
      treating patients with acute leukemia or chronic myelogenous leukemia in blast phase.&#xD;
      Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the dose-limiting toxicity and maximum tolerated dose of tipifarnib and&#xD;
      bortezomib in patients with relapsed or refractory acute myeloid leukemia, acute&#xD;
      lymphoblastic leukemia, or chronic myeloid leukemia in blast phase.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the effect of this regimen on farnesyltransferase and proteasome inhibition in&#xD;
      peripheral blood mononuclear cells in these patients.&#xD;
&#xD;
      II. Determine the clinical efficacy of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and oral tipifarnib&#xD;
      twice daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with partial response or stable&#xD;
      disease may continue therapy beyond 6 courses at the discretion of the investigator.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib and tipifarnib until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Blood is collected periodically for protein expression studies. Bone marrow aspirates&#xD;
      obtained at baseline are examined by immunohistochemistry for Ki-67 activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in apoptotic protein expression (Bim, Bax, AKT)</measure>
    <time_frame>Baseline and day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy (response rate) evaluated using the revised International Working Group Criteria (IWG) for AML</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia</condition>
  <condition>Adult Acute Monoblastic Leukemia</condition>
  <condition>Adult Acute Monocytic Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With Maturation</condition>
  <condition>Adult Acute Myeloid Leukemia With Minimal Differentiation</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL</condition>
  <condition>Adult Acute Myeloid Leukemia Without Maturation</condition>
  <condition>Adult Acute Myelomonocytic Leukemia</condition>
  <condition>Adult Erythroleukemia</condition>
  <condition>Adult Pure Erythroid Leukemia</condition>
  <condition>Blastic Phase</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Disease</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipifarnib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>R115777</other_name>
    <other_name>Zarnestra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets 1 of the following disease-specific criteria:&#xD;
&#xD;
               -  Relapsed disease after =&lt; 2 prior chemotherapy regimens (consolidation therapy&#xD;
                  excluded)&#xD;
&#xD;
               -  Primary-induction failure&#xD;
&#xD;
               -  Previously untreated and deemed unfit for or refusing cytotoxic chemotherapy&#xD;
&#xD;
          -  No hyperleukocytosis (leukemic blasts &gt;= 30,000/mm^3)&#xD;
&#xD;
          -  No acute promyelocytic leukemia (M3)&#xD;
&#xD;
          -  No active CNS leukemia&#xD;
&#xD;
          -  SGOT and SGPT =&lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled hypertension, congestive heart failure, angina pectoris, or&#xD;
             ventricular dysrhythmias&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No uncontrolled disseminated intravascular coagulation&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
               -  Hormonal contraception must have been initiated â‰¥ 1 month prior to study entry&#xD;
&#xD;
          -  No active graft-vs-host disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No intrinsic impaired organ function&#xD;
&#xD;
          -  No known allergy to imidazole drugs&#xD;
&#xD;
          -  No neuropathy &gt;= grade 1&#xD;
&#xD;
          -  No known hypersensitivity to bortezomib, tipifarnib, boron, or mannitol&#xD;
&#xD;
          -  No physical or psychiatric conditions that would preclude study participation,&#xD;
             including poorly controlled psychosis&#xD;
&#xD;
          -  At least 48 hours since prior hydroxyurea&#xD;
&#xD;
          -  No prior tipifarnib, bortezomib, or investigational proteasomal inhibitors&#xD;
&#xD;
          -  No concurrent radiotherapy, chemotherapy, or immunotherapy&#xD;
&#xD;
          -  No concurrent enzyme-inducing antiepileptic medications (e.g., phenytoin,&#xD;
             phenobarbital, or carbamazepine)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  LVEF &gt;= 40%&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia in blast phase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Lancet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

